Get the Stockscreener App
15.10
4.79%
-0.76
Pre-market:
15.10
Tonix Pharmaceuticals Holding Corp stock is traded at $15.10, with a volume of 364.77K.
It is down -4.79% in the last 24 hours and down -4.25% over the past month.
Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as major depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$15.86
Open:
$15.81
24h Volume:
364.77K
Relative Volume:
0.66
Market Cap:
$193.10M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.341
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+1.00%
1M Performance:
-4.25%
6M Performance:
-74.73%
1Y Performance:
+31.30%
1-Day Range:
$14.98
$15.81
1-Week Range:
$14.98
$16.69
52-Week Range:
$7.31
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
15.10 | 202.82M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
TNXP News Today | Why did Tonix Pharmaceuticals stock drop today? - MarketBeat
Behavioral Patterns of TNXP and Institutional Flows - Stock Traders Daily
Market Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M APortfolio Value Report & Safe Capital Growth Stock Tips - baoquankhu1.vn
Earnings Recap: Can Tonix Pharmaceuticals Holding Corp deliver alphaJuly 2025 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
Dying for Some Sleep - RealClearHealth
Tonix opens Berkeley Heights HQ, expands NJ biotech footprint - NJBIZ
Aug Opening: How volatile is Haverty Furniture Companies Inc stockPortfolio Risk Report & Verified High Yield Trade Plans - baoquankhu1.vn
Tonix’s fibromyalgia drug shows significant pain reduction in study By Investing.com - Investing.com Australia
Tonix Highlights Significant Phase 3 RESILIENT Results For TONMYA At Non-Opioid Pain Summit - Nasdaq
Tonix Presents Positive Phase 3 RESILIENT Data On TONMYA At 2026 Non-Opioid Pain Therapeutics Summit - Nasdaq
Tonix Pharmaceuticals (TNXP) Reports Positive Phase 3 Trial Resu - GuruFocus
Tonix’s fibromyalgia drug shows significant pain reduction in study - Investing.com
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - The Manila Times
Pharma company Tonix opening HQ in Berkeley Heights - ROI-NJ
Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchart.com
(TNXP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A. G. P. Maintains Tonix Pharmaceuticals(TNXP.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Trend Review: Is now the right time to enter Tonix Pharmaceuticals Holding CorpEarnings Overview Report & High Return Trade Guides - baoquankhu1.vn
Aug Wrap: Is Tonix Pharmaceuticals Holding Corp forming a breakout patternJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Tonix Eyes TNX‑102 SL Expansion, But We Need To See Tonmya Revenue First (NASDAQ:TNXP) - Seeking Alpha
How (TNXP) Movements Inform Risk Allocation Models - Stock Traders Daily
Returns Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M A2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Market Fear: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear market2025 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Aug PostEarnings: What are Tonix Pharmaceuticals Holding Corps earnings expectationsWeekly Volume Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Analyst Downgrade: Will Tonix Pharmaceuticals Holding Corp face regulatory challengesJuly 2025 Momentum & Technical Confirmation Alerts - baoquankhu1.vn
Fibromyalgia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates - openPR.com
Block Trades: What is the fair value of Tonix Pharmaceuticals Holding Corp. stock now2025 Key Highlights & Reliable Intraday Trade Plans - moha.gov.vn
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockBreakout Watch & Verified Momentum Watchlists - Улправда
Take Profit: How analysts rate Tonix Pharmaceuticals Holding Corp. stock todayWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingWatch List & Stepwise Swing Trade Plans - Улправда
Can Tonix Pharmaceuticals Holding Corp. stock withstand economic slowdownJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Key Highlights & Trade Opportunity Analysis - ulpravda.ru
Trading Systems Reacting to (TNXP) Volatility - Stock Traders Daily
Daily News - FinancialContent
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - The Manila Times
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals to meet with FDA in 2026 to advance experimental Lyme disease prevention drug - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):